Prelude Capital Management’s Intersect ENT, Inc XENT Stock Holding History

Prelude Capital Management’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100	Closed	-$2K	–	2206
2019 Q2	$2K	Buy	+100	New	+$2.7K	﹤0.01%	1587
2019 Q1	–	Sell	-100	Closed	-$3K	–	2325
2018 Q4	$3K	Buy	+100	New	+$2.93K	﹤0.01%	1675

Prelude Capital Management's XENT Position: Q2 2022 in Review

Prelude Capital Management sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 197,047 shares — an estimated $5.52M sold.

Prelude Capital Management first reported a position in XENT in Q3 2015 and held it in 13 quarters. The position peaked at $5.52M in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

Prelude Capital Management reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
Prelude Capital Management sold 197,047 Intersect ENT, Inc shares in Q2 2022, an estimated $5.52M.
Prelude Capital Management first reported a position in Intersect ENT, Inc in Q3 2015 and held it in 13 quarters.
Prelude Capital Management's Intersect ENT, Inc position peaked at $5.52M in Q1 2022.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.